# US 12,006,544 B2 · Safe sequencing system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,544 B2
- Document ID: US12006544B2
- Status: Granted
- Kind: B2
- Application number: 18/519,727
- Filed: 2023-11-27
- Published: 2024-03-28
- Granted: 2024-06-11
- Earliest claimed: 2011-04-15
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Bert Vogelstein; Kenneth W. Kinzler; Nickolas Papadopoulos; Isaac A. Kinde
- Web page: https://patentgrep.com/patent/US12006544B2

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2525/179: incorporating arbitrary or random nucleotide sequences
- C12Q 2525/191: incorporating an adaptor
- C12Q 2563/179: the label being a nucleic acid
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.

## Claims

### Claim 1

A method comprising:
a) subjecting an initial double-stranded template molecule comprising a unique identifier sequence (UID), or amplicons thereof, to paired-end sequencing on a massively parallel sequencer to generate first strand UID-labelled paired-end reads and second strand UID-labelled paired-end reads; and
b) differentiating which strand of said initial double-stranded template molecule is represented by said first and second strand UID-labelled paired-end reads based on the observed orientation and order of said UID as it appears in said first and second strand UID-labelled paired-end reads when sequence information is obtained from said paired-end sequencing.

### Claim 2 (depends on 1)

The method of claim 1, wherein said UID is 2 to 1000 bases in length.

### Claim 3 (depends on 1)

The method of claim 1, wherein said UID is 4 to 400 bases in length.

### Claim 4 (depends on 1)

The method of claim 1, wherein said initial double-stranded template molecule comprises a mutation, and wherein the method further comprises: c) determining which strand or strands of said initial double-stranded template molecule comprises a mutation based on said differentiating.

### Claim 5 (depends on 4)

The method of claim 4, wherein said determining which strand or strands of said initial double-stranded template molecule has a mutation comprises determining that both strands are mutated.

### Claim 6 (depends on 5)

The method of claim 5, wherein both strands are determined to be mutated at the same position.

### Claim 7 (depends on 1)

The method of claim 1, wherein said paired-end sequencing yields a first family and a second family, wherein said first family comprises said first strand UID-labelled paired end reads and said second family comprises said second strand UID-labelled paired-end reads.

### Claim 8 (depends on 7)

The method of claim 7, further comprising: comparing determined nucleotide sequences between members of said first family, and comparing determined nucleotide sequences between members of said second family.

### Claim 9 (depends on 8)

The method of claim 8, further comprising identifying a nucleotide sequence as accurately representing said initial double-stranded template molecule when at least 50% of members of said first family, or said second family, contain the sequence.

### Claim 10 (depends on 8)

The method of claim 8, further comprising identifying a nucleotide sequence as accurately representing said initial double-stranded template molecule when at least 70% of members of said first family, or said second family, contain the sequence.

### Claim 11 (depends on 8)

The method of claim 8, wherein said determining which strand or strands of said initial double-stranded template molecule has a mutation comprises identifying a mutation in the same position in at least 50% of said first strand UID-labelled paired end reads in said first family, and/or identifying a mutation in the same position of at least 50% of said second strand UID-labelled paired-end reads in said second family.

### Claim 12 (depends on 11)

The method of claim 11, wherein said mutation is selected from:
a single base substitution, an insertion, or a deletion.

### Claim 13 (depends on 8)

The method of claim 8, wherein said determining which strand or strands of said initial double-stranded template molecule has a mutation comprises identifying a mutation in the same position in at least 70% of said first strand UID-labelled paired end reads in said first family, and/or identifying a mutation in the same position of at least 70% of said second strand UID-labelled paired-end reads in said second family.

### Claim 14 (depends on 13)

The method of claim 13, wherein said mutation is selected from: a single base substitution, an insertion, or a deletion.

### Claim 15 (depends on 1)

The method of claim 1, wherein said UID comprises an endogenous UID.

### Claim 16 (depends on 1)

The method of claim 1, wherein said UID comprises an exogenous UID.

### Claim 17 (depends on 1)

The method of claim 1, wherein said UID of said initial double-stranded template molecule is a first UID, and wherein said initial double-stranded template molecule further comprises a second UID.

### Claim 18 (depends on 17)

The method of claim 17, wherein said first and second UIDs are selected from endogenous and/or exogenous UIDs.

### Claim 19 (depends on 1)

The method of claim 1, wherein said UID is added to said initial double-stranded template molecule by ligation.

### Claim 20 (depends on 1)

The method of claim 1, wherein said UID is added to said initial double-stranded template molecule by PCR.